Size-selective hemoperfusion polymeric adsorbents
    14.
    发明授权
    Size-selective hemoperfusion polymeric adsorbents 有权
    大小选择性血液灌注聚合物吸附剂

    公开(公告)号:US07875182B2

    公开(公告)日:2011-01-25

    申请号:US11601931

    申请日:2006-11-20

    摘要: Size-selective hemocompatible porous polymeric adsorbents are provided with a pore structure capable of excluding molecules larger than 50,000 Daltons, but with a pore system that allows good ingress and egress of molecules smaller than 35,000 Daltons. The pore system in these porous polymeric adsorbents is controlled by the method of synthesis so that 98% of the total pore volume is located in pores smaller than 300 Angstroms (Å) in diameter with a working pore size range within 100 to 300 Å in diameter. The porous polymeric adsorbents of this invention are very selective for extracting midsize proteins, such as cytokines and β2-microglobulin, from blood and other physiologic fluids while keeping the components required for good health such as cells, platelets, albumin, hemoglobin, fibrinogen, and other serum proteins intact.

    摘要翻译: 尺寸选择性血液相容性多孔聚合物吸附剂具有能够排除大于50,000道尔顿分子的孔结构,但具有允许良好的进入和流出小于35,000道尔顿的分子的孔系统。 这些多孔聚合物吸附剂中的孔隙体系通过合成方法控制,使得总孔体积的98%位于直径小于300埃(孔)的孔中,其工作孔径范围在100至300埃范围内 。 本发明的多孔聚合物吸附剂对于从血液和其他生理液中提取中等蛋白质,例如细胞因子和β-微球蛋白是非常有选择性的,同时保持良好健康所需的组分,例如细胞,血小板,白蛋白,血红蛋白,纤维蛋白原 ,和其他血清蛋白完整。

    Size-selective hemoperfusion polymeric adsorbents
    15.
    发明申请
    Size-selective hemoperfusion polymeric adsorbents 有权
    大小选择性血液灌注聚合物吸附剂

    公开(公告)号:US20080119576A1

    公开(公告)日:2008-05-22

    申请号:US11601931

    申请日:2006-11-20

    IPC分类号: B01D15/34

    摘要: Size-selective hemocompatible porous polymeric adsorbents are provided with a pore structure capable of excluding molecules larger than 50,000 Daltons, but with a pore system that allows good ingress and egress of molecules smaller than 35,000 Daltons. The pore system in these porous polymeric adsorbents is controlled by the method of synthesis so that 98% of the total pore volume is located in pores smaller than 300 Angstroms (Å) in diameter with a working pore size range within 100 to 300 Å in diameter. The porous polymeric adsorbents of this invention are very selective for extracting midsize proteins, such as cytokines and β2-microglobulin, from blood and other physiologic fluids while keeping the components required for good health such as cells, platelets, albumin, hemoglobin, fibrinogen, and other serum proteins intact.

    摘要翻译: 尺寸选择性血液相容性多孔聚合物吸附剂具有能够排除大于50,000道尔顿分子的孔结构,但具有允许良好的进入和流出小于35,000道尔顿的分子的孔系统。 这些多孔聚合物吸附剂中的孔隙体系通过合成方法控制,使得总孔体积的98%位于直径小于300埃(孔)的孔中,其工作孔径范围在100至300埃范围内 。 本发明的多孔聚合物吸附剂对于从血液和其它生理液中提取中等蛋白质,例如细胞因子和β2 - 微球蛋白是非常有选择性的,同时保持良好健康所需的组分如细胞,血小板 ,白蛋白,血红蛋白,纤维蛋白原等完整的血清蛋白。

    Psychotropic polycyclic imides
    17.
    发明授权
    Psychotropic polycyclic imides 失效
    精神药物多环酰胺

    公开(公告)号:US4797488A

    公开(公告)日:1989-01-10

    申请号:US34820

    申请日:1987-04-03

    摘要: Substituted imides of the following formula are antipsychotic, anxiolytic agents with very little extrapyramidal side effects: ##STR1## in which X is --O--, --S--, --SO--, --SO.sub.2 --, --CR.sub.3 R.sub.4 -- where R.sub.3 and R.sub.4, independently, are hydrogen, alkyl of 1 to 4 carbon atoms or, taken together with the carbon atom to which they are attached, R.sub.3 and R.sub.4 form a cycloalkyl group of of 3 to 5 carbon atoms; n is one of the integers 2, 3, 4 or 5; R is phenyl, halophenyl, trifluoromethylphenyl, alkoxyphenyl in which the alkoxy substituent contains 1 to 3 carbon atoms, 2-pyrimidinyl, halopyrimidin-2-yl, 2-pyrazinyl, halopyrazin-2-yl, 2-pyridinyl, cyanopyridin-2-yl, halopyridin-2-yl, quinolyl, or haloquinolyl; R.sub.1 and R.sub.2, taken together, are alkylene of 3 to 5 carbon atoms or alkenylene of 3 to 5 carbon atoms, or taken with the carbon atoms to which they are attached, R.sub.1 and R.sub.2 complete a benzene ring, or a group of the formula: ##STR2## where Y is --CH.sub.2 --, --CH.sub.2 --CH.sub.2 --, --O-- or --S-- and the dotted line represents optional unsaturation; or a pharmaceutically acceptable salt thereof. In addition, the intermediate b3-dicarboxylic and the corresponding anhydrides - 2,3,3a,3b,4,5,6,6a,7,7a-decahydro-4,6,7-metheno-1H-cyclopenta[a]pentalene-1,3-dicarboxylic acid and octahydro-1,5-methano-6,8,9-metheneopentaleno[1,2-d]oxepin-2,4(1H,5H)-dione represent especially significant aspects of the invention.